INtRON Biotechnology Inc.

Seongnam, South Korea

INtRON Biotechnology Inc.

Seongnam, South Korea

Time filter

Source Type

The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or the genus Candida, and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus Cryptococcus or the genus Candida, the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.


The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or the genus Candida, and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus Cryptococcus or the genus Candida, the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention, is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.


The present invention relates to an FK506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-FK506, 31-O-demethyl-FK506, or 9-deoxo-31-O-demethyl-FK506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.


The present invention relates to an FK506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-FK506, 31-O-demethyl-FK506, or 9-deoxo-31-O-demethyl-FK506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.


Patent
INtRON Biotechnology Inc. | Date: 2014-06-26

The present invention relates to a composition comprising EK99P-1, a bacteriophage isolated from nature and capable of infecting E. coli type K99 so as to kill the same, as an active ingredient, and a method for preventing and treating E. coli type K99 infections using the said composition. According to the present invention, the bacteriophage EK99P-1, an active ingredient of the composition, has a killing activity against E. coli type K99 and has the genome represented by SEQ. ID. NO: 1.


Patent
INtRON Biotechnology Inc. | Date: 2014-01-01

The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.


Patent
INtRON Biotechnology Inc. | Date: 2015-11-06

The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying Salmonella once being infected in Salmonella, as an active ingredient, and a method for prevention and treatment of Salmonella infection using the same. Bacteriophage SP-1, the active ingredient of the composition of the present invention, characteristically has the killing activity to Salmonella and has the genome represented by SEQ. ID. NO: 1.


Patent
INtRON Biotechnology Inc. | Date: 2015-04-28

A composition includes an isolated bacteriophage Str-PAP-1 having the ability to kill Streptococcus parauberis cells specifically by infecting the same, and may be used to prevent and treat Streptococcus parauberis infections. The bacteriophage Str-PAP-1 that is an active ingredient of the composition has the ability to kill Streptococcus parauberis cells and characteristically has the genome represented by nucleotide sequence of SEQ. ID. NO: 1.


The present invention relates to a composition comprising the bacteriophage EK88P-1 isolated from the nature and having a broad antibacterial spectrum against E. coli as an active ingredient, and a method for preventing and treating E. coli infections using the said composition. The bacteriophage EK88P-1, the active ingredient of the composition of the present invention, has a broad antibacterial spectrum against E. coli and has the genome characteristically composed of the partial nucleotide sequences represented by SEQ. ID. NO: 1NO: 25, and also characterized by the bacteriophage belonging to the Myoviridae family according to the morphology that is composed of the major structural proteins in the sizes of approximately 49 kDa, 53 kDa, 94 kDa, and 103 kDa.


Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.

Loading INtRON Biotechnology Inc. collaborators
Loading INtRON Biotechnology Inc. collaborators